NICE Approval8 Aug 2022 14:15
"genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS".
From RNS on June 16th. One would think this evaluation process must be almost done. Once the results are announced, assuming NICE decree that GDR's AIHL test meets their standards and they recommend the test, I'd expect rapid and extensive deployment throughout the NHS. I think this is what the market is waiting for and when achieved should unleash the SP to multiples of where it's at today. Of course if they don't recommend the test .........